CHPA Looks For FDA Reform Legislation To Deliver Monograph Changes In 2016
This article was originally published in The Tan Sheet
Executive Summary
CHPA chief Scott Melville is optimistic for OTC monograph reform progress in 2016. In an interview about CHPA's 2016 priorities, Melville also said state and local environmental regulations that touch OTC drugs will garner attention.
You may also be interested in...
PDUFA Negotiations Begin With FDA Seeking Review System Reform
During the inaugural negotiating session for renewal of PDUFA, which covers OTC switch and other nonprescription product NDAs, FDA says among its goals are “enhancements to the review processes.” The five-hour session included the ground rules for the talks and FDA and industry representatives also laid out their general wants and needs.
Unfettered OTC Purchasing With Pre-Tax Savings Tops CHPA Goals In 2015
CHPA is optimistic 2015 is the year “common sense” will restore OTC eligibility for health spending accounts. Speaking on the group’s priorities, President and CEO Scott Melville said CHPA will work to improve the OTC monograph system and to curb cough medicine abuse.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.